Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.

Technetium (99mTc) votumumab

Другие языки:

Tiếng Việt

Technetium (99mTc) votumumab

Подписчиков: 0, рейтинг: 0

Technetium (^99mTc) votumumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	tumor antigen CTAA16.88
Clinical data
ATC code	V09IA04 (WHO)
Legal status
Legal status	not marketed
Identifiers
CAS Number	148189-70-2^N
ChemSpider	none
UNII	63635D7SGF
^NY (what is this?) (verify)

Technetium (^99mTc) votumumab (trade name HumaSPECT) is a human monoclonal antibody labelled with the radionuclide technetium-99m. It was developed for the detection of colorectal tumors, but has never been marketed.

The target of votumumab is CTAA16.88, a complex of cytokeratin polypeptides in the molecular weight range of 35 to 43 kDa, which is expressed in colorectal tumors.

Diagnostic radiopharmaceuticals (V09)

Central nervous system

Skeletal system

^99mTc (Medronic acid)

Renal

Gastrointestinal/Hepatic

⁷⁵Se (SeHCAT)

Respiratory system

Cardiovascular system

Inflammation/infection

Tumor

Adrenal cortex

¹²³I
¹²⁵I / ¹³¹I (Iodocholesterol)

Radionuclides
(including tracers)

positron (PET list)

¹¹C ([¹¹C]ME@HAPTHI)
25B-NBOMe (Cimbi-36)
Acetate
Choline
Carfentanil
DASB
DTBZ
Flumazenil
Methionine
N-Methylspiperone
Pittsburgh compound B
Raclopride
Verapamil)
¹³N
- Ammonia
⁶⁴Cu
Desmethoxyfallypride
Fallypride
Florbetaben
Florbetapir
Flortaucipir (¹⁸F)
Flubatine
Fluciclovine
Fludeoxyglucose (¹⁸F) (FDG)-glucose analogue
Flumazenil
¹⁸F (Altanserin)
Fluorocholine
Fluorodeoxysorbitol (FDS)
Fluorodopa
Fluoroestradiol F-18
Fluorothymidine F-18
Fluspidine
Flutemetamol
FMISO
Gallium (⁶⁸Ga) gozetotide
⁶⁸Ga
Mefway
MPPF
N-Methylspiperone
Nifene
FET
¹⁵O (Water)
Piflufolastat F-18
⁸²Rb (Rubidium chloride)
Setoperone)

gamma ray/photon (SPECT/scintigraphy)

Isotopes used:

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab^§ Amivantamab Ascrinvacumab^§ Atezolizumab Balstilimab^† Botensilimab Cixutumumab^§ Conatumumab^§ Daratumumab Drozitumab^§ Duligotumab^§ Dusigitumab^§ Enfortumab vedotin Enoticumab^§ Figitumumab^§ Flanvotumab^§ Ganitumab^† Glembatumumab vedotin^† Intetumumab^§ Ipilimumab Iratumumab^§ Istiratumab Icrucumab^§ Lexatumumab^§ Lucatumumab^§ Mapatumumab^§ Narnatumab^§ Necitumumab Nesvacumab^§ Nivolumab^# Ofatumumab Olaratumab^† Panitumumab Patritumab^§ Pembrolizumab^# Pritumumab^§ Radretumab^§ Ramucirumab Rilotumumab^† Robatumumab^§ Seribantumab^§ Tarextumab^§ Tisotumab vedotin Teprotumumab^† Tovetumab^§ Vantictumab^§ Votumumab^§ Zalutumumab^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab^§ Bavituximab^§ Brentuximab vedotin Carotuximab^† Cetuximab Derlotuximab biotin^§ Dinutuximab Ecromeximab^§ Ensituximab^§ Futuximab^§ Girentuximab^† Indatuximab ravtansine^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab^# Siltuximab Ublituximab
Humanized	Abituzumab^§ Alemtuzumab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine^§ Brontictuzumab^§ Cantuzumab mertansine^§ Cantuzumab ravtansine^§ Cirmtuzumab Citatuzumab bogatox^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab^§ Demcizumab^§ Dalotuzumab^§ Denintuzumab mafodotin^§ Elotuzumab Emactuzumab Emibetuzumab^§ Enoblituzumab^§ Etaracizumab^§ Farletuzumab^§ Ficlatuzumab^§ Flotetuzumab^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab^§ Inotuzumab ozogamicin Labetuzumab^§ Lifastuzumab vedotin^§ Lintuzumab^§ Lorvotuzumab mertansine^§ Lumretuzumab^§ Matuzumab^§ Milatuzumab^§ Naxitamab Nimotuzumab^† Obinutuzumab Ocaratuzumab^§ Otlertuzumab^§ Onartuzumab^§ Oportuzumab monatox^† Parsatuzumab^§ Pertuzumab Pinatuzumab vedotin^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine^† Sacituzumab govitecan Sibrotuzumab^§ Simtuzumab^§ Sofituzumab vedotin^§ Tacatuzumab tetraxetan^§ Tigatuzumab^§ Trastuzumab^# (+deruxtecan / +emtansine) Tucotuzumab celmoleukin^§ Vandortuzumab vedotin^§ Vanucizumab^§ Veltuzumab^§ Vorsetuzumab mafodotin^§ PankoMab
Rat/mouse hybrid	Catumaxomab Ertumaxomab^§
Chimeric + humanized	Depatuxizumab mafodotin^† Duvortuxizumab Ontuxizumab^§

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III